Physician profile
Scott R Johnson
NPI 1497761134
$1,902.79
in general payments reported to CMS, 2019-2025
29 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $222 · 2021: $353 · 2022: $396 · 2023: $222 · 2024: $261 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $259.66 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $198.82 | 2022-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $185.09 | 2019-2025 | |
| Abbvie INC. | $141.02 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.37 | 2021-2024 | |
| Amgen INC. | $119.02 | 2019-2024 | Evenity, Prolia |
| Lilly USA, LLC | $108.57 | 2020-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $76.83 | 2019-2025 | Spravato |
| Exact Sciences Corporation | $76.60 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $70.94 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $55.94 | 2021-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.67 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $45.35 | 2020-2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $44.51 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.69 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $37.85 | 2025 | Rexulti |
| Genentech USA, INC. | $37.58 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $33.01 | 2022-2023 | Leqvio |
| Boston Scientific Corporation | $29.99 | 2022 | |
| Medtronic, INC. | $29.62 | 2025 | Symplicity G3 |
| Dexcom, INC. | $23.61 | 2021-2022 | |
| Scpharmaceuticals INC. | $16.95 | 2025 | |
| Merck Sharp & Dohme LLC | $15.96 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Ultragenyx Pharmaceutical INC. | $14.20 | 2021 | |
| Eisai INC. | $14.07 | 2021 | |
| Mylan Specialty L.P. | $14.03 | 2024 | Yupelri |
| Abbott Laboratories | $13.80 | 2024 | Eterna |
| Teva Pharmaceuticals USA, INC. | $13.03 | 2021 | |
| Mannkind Corporation | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.